DOCSLIB.ORG

Drug Tariff Price Changes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Drug tariff February 2017 Top 10 price reductions since January 2017 Medicine Pack size Basic price January 2017 Difference Chloral hydrate 143.3mg/5ml oral solution BP 150 ml £244.25 £274.90 -£30.65 Linezolid 600mg tablets 10 tablet £333.82 £360.06 -£26.24 Doxepin 50mg capsules 28 capsule £154.00 £175.18 -£21.18 Cloral betaine 707mg tablets 30 tablet £138.59 £155.98 -£17.39 Olsalazine 500mg tablets 60 tablet £161.00 £177.10 -£16.10 Budesonide 3mg gastro-resistant modified-release capsules 100 capsule £84.15 £99.00 -£14.85 Olsalazine 250mg capsules 112 capsule £144.00 £158.40 -£14.40 Mesalazine 800mg gastro-resistant tablets 180 tablet £80.75 £95.00 -£14.25 Doxepin 25mg capsules 28 capsule £97.00 £110.34 -£13.34 Methocarbamol 750mg tablets 100 tablet £45.02 £55.80 -£10.78 Top 10 price increases since January 2017 Medicine Pack size Basic price January 2017 Difference Quinagolide 75microgram tablets 30 tablet £55.00 £27.00 £28.00 Ampicillin 500mg capsules 28 capsule £40.30 £20.50 £19.80 Ampicillin 250mg capsules 28 capsule £20.50 £4.52 £15.98 Sulfadiazine 500mg tablets 56 tablet £109.37 £99.57 £9.80 Isocarboxazid 10mg tablets 56 tablet £197.95 £188.95 £9.00 Menadiol 10mg tablets 100 tablet £185.90 £177.45 £8.45 Atropine 1% eye drops 10 ml £80.34 £73.52 £6.82 Tamoxifen 40mg tablets 30 tablet £38.09 £33.50 £4.59 Ephedrine hydrochloride 30mg tablets 28 tablet £44.46 £40.25 £4.21 Testosterone enantate 250mg/1ml solution for injection ampoules 3 ampoule £79.75 £76.13 £3.62 Page 1 of 6 Top 25 price reductions since November 2016 Medicine Pack size Basic price November 2016 Difference Linezolid 600mg tablets 10 tablet £333.82 £392.86 -£59.04 Sevelamer 800mg tablets 180 tablet £48.87 £74.11 -£25.24 Nefopam 30mg tablets 90 tablet £51.00 £66.11 -£15.11 Budesonide 3mg gastro-resistant modified-release capsules 100 capsule £84.15 £99.00 -£14.85 Trazodone 100mg capsules 56 capsule £23.89 £38.63 -£14.74 Mesalazine 800mg gastro-resistant tablets 180 tablet £80.75 £95.00 -£14.25 Carbimazole 20mg tablets 100 tablet £166.71 £178.89 -£12.18 Aripiprazole 30mg tablets 28 tablet £22.83 £34.38 -£11.55 Trazodone 50mg/5ml oral solution sugar free 120 ml £151.49 £162.85 -£11.36 Methocarbamol 750mg tablets 100 tablet £45.02 £55.80 -£10.78 Rasagiline 1mg tablets 28 tablet £3.15 £13.38 -£10.23 Nortriptyline 25mg tablets 100 tablet £31.72 £41.44 -£9.72 Famciclovir 500mg tablets 14 tablet £147.20 £156.86 -£9.66 Pioglitazone 45mg tablets 28 tablet £2.62 £11.71 -£9.09 Pioglitazone 30mg tablets 28 tablet £1.99 £10.89 -£8.90 Acetazolamide 250mg tablets 112 tablet £28.20 £36.51 -£8.31 Nortriptyline 10mg tablets 100 tablet £31.50 £39.30 -£7.80 Dicycloverine 10mg/5ml oral solution 120 ml £176.08 £183.27 -£7.19 Pioglitazone 15mg tablets 28 tablet £1.84 £8.23 -£6.39 Dexamethasone 2mg tablets 50 tablet £42.85 £49.00 -£6.15 Carbimazole 5mg tablets 100 tablet £62.37 £68.12 -£5.75 Hydrocortisone 10mg tablets 30 tablet £68.67 £74.40 -£5.73 Trazodone 50mg capsules 84 capsule £24.43 £29.85 -£5.42 Clindamycin 150mg capsules 24 capsule £3.81 £8.97 -£5.16 Fluvoxamine 100mg tablets 30 tablet £20.34 £25.25 -£4.91 Top 25 price increases since November 2016 Medicine Pack size Basic price November 2016 Difference Prednisolone 20mg/application foam enema 14 dose £187.00 £78.00 £109.00 Ethosuximide 250mg capsules 56 capsule £173.00 £73.20 £99.80 Mefenamic acid 50mg/5ml oral suspension 125 ml £179.00 £79.98 £99.02 Betamethasone valerate 0.1% / Neomycin 0.5% cream 100 gram £104.52 £59.14 £45.38 Betamethasone valerate 0.1% / Neomycin 0.5% ointment 100 gram £104.52 £59.14 £45.38 Bumetanide 1mg/5ml oral solution sugar free 150 ml £198.00 £168.00 £30.00 Quinagolide 75microgram tablets 30 tablet £55.00 £27.00 £28.00 Amiloride 5mg / Bumetanide 1mg tablets 28 tablet £56.00 £29.60 £26.40 Mebeverine 50mg/5ml oral suspension sugar free 300 ml £187.00 £163.43 £23.57 Clobetasol 500microgram / Neomycin 5mg / Nystatin 100,000units/g cream30 gram £87.00 £64.00 £23.00 Clobetasol 500microgram / Neomycin 5mg / Nystatin 100,000units/g ointment30 gram £87.00 £64.00 £23.00 Alimemazine 30mg/5ml oral solution 100 ml £243.51 £221.37 £22.14 Atropine 1% eye drops 10 ml £80.34 £59.28 £21.06 Ampicillin 500mg capsules 28 capsule £40.30 £20.50 £19.80 Isocarboxazid 10mg tablets 56 tablet £197.95 £179.95 £18.00 Menadiol 10mg tablets 100 tablet £185.90 £169.00 £16.90 Alimemazine 7.5mg/5ml oral solution 100 ml £179.54 £163.21 £16.33 Sulfadiazine 500mg tablets 56 tablet £109.37 £93.47 £15.90 Ampicillin 250mg capsules 28 capsule £20.50 £5.42 £15.08 Betamethasone valerate 0.1% / Neomycin 0.5% cream 30 gram £31.36 £17.74 £13.62 Betamethasone valerate 0.1% / Neomycin 0.5% ointment 30 gram £31.36 £17.74 £13.62 Ropinirole 500microgram tablets 28 tablet £13.63 £2.23 £11.40 Alimemazine 10mg tablets 28 tablet £112.85 £102.59 £10.26 Betamethasone valerate 0.1% / Clioquinol 3% cream 30 gram £38.88 £28.88 £10.00 Betamethasone valerate 0.1% / Clioquinol 3% ointment 30 gram £38.88 £28.88 £10.00 Page 2 of 6 Top 100 price reductions since February 2016 Medicine Pack size Basic price February 2016 Difference Aripiprazole 30mg tablets 28 tablet £22.83 £120.15 -£97.32 Carbimazole 20mg tablets 100 tablet £166.71 £261.89 -£95.18 Nortriptyline 25mg tablets 100 tablet £31.72 £103.77 -£72.05 Rasagiline 1mg tablets 28 tablet £3.15 £70.72 -£67.57 Sevelamer 800mg tablets 180 tablet £48.87 £104.02 -£55.15 Acetazolamide 250mg tablets 112 tablet £28.20 £77.45 -£49.25 Carbimazole 5mg tablets 100 tablet £62.37 £108.62 -£46.25 Nortriptyline 10mg tablets 100 tablet £31.50 £73.68 -£42.18 Mesalazine 800mg gastro-resistant tablets 180 tablet £80.75 £117.62 -£36.87 Duloxetine 40mg gastro-resistant capsules 56 capsule £4.89 £26.69 -£21.80 Mesalazine 1.2g gastro-resistant modified-release tablets 60 tablet £42.95 £62.44 -£19.49 Hydrocortisone 10mg tablets 30 tablet £68.67 £87.85 -£19.18 Aripiprazole 10mg tablets 28 tablet £1.76 £20.81 -£19.05 Aripiprazole 5mg tablets 28 tablet £1.60 £20.63 -£19.03 Eplerenone 25mg tablets 28 tablet £4.14 £22.93 -£18.79 Aripiprazole 15mg tablets 28 tablet £1.86 £20.24 -£18.38 Eplerenone 50mg tablets 28 tablet £5.37 £22.66 -£17.29 Colchicine 500microgram tablets 100 tablet £14.28 £30.24 -£15.96 Nebivolol 2.5mg tablets 28 tablet £31.52 £47.34 -£15.82 Duloxetine 60mg gastro-resistant capsules 28 capsule £2.37 £17.46 -£15.09 Atomoxetine 4mg/1ml oral solution sugar free 300 ml £85.00 £100.00 -£15.00 Budesonide 3mg gastro-resistant modified-release capsules 100 capsule £84.15 £99.00 -£14.85 Lormetazepam 1mg tablets 30 tablet £8.07 £21.20 -£13.13 Duloxetine 30mg gastro-resistant capsules 28 capsule £2.10 £15.15 -£13.05 Atomoxetine 100mg capsules 28 capsule £70.79 £83.28 -£12.49 Atomoxetine 80mg capsules 28 capsule £70.79 £83.28 -£12.49 Clomifene 50mg tablets 30 tablet £10.15 £21.74 -£11.59 Tranylcypromine 10mg tablets 28 tablet £235.89 £247.24 -£11.35 Riluzole 50mg tablets 56 tablet £14.37 £25.72 -£11.35 Tiotropium bromide 2.5micrograms/dose solution for inhalation cartridge with60 devicedose CFC free£23.00 £33.50 -£10.50 Duloxetine 20mg gastro-resistant capsules 28 capsule £2.94 £13.44 -£10.50 Atomoxetine 10mg capsules 28 capsule £53.09 £62.46 -£9.37 Atomoxetine 18mg capsules 28 capsule £53.09 £62.46 -£9.37 Atomoxetine 25mg capsules 28 capsule £53.09 £62.46 -£9.37 Atomoxetine 40mg capsules 28 capsule £53.09 £62.46 -£9.37 Atomoxetine 60mg capsules 28 capsule £53.09 £62.46 -£9.37 Metronidazole 200mg tablets 21 tablet £2.65 £11.66 -£9.01 Apixaban 2.5mg tablets 60 tablet £57.00 £65.90 -£8.90 Glyceryl trinitrate 500microgram sublingual tablets 100 tablet £5.73 £14.31 -£8.58 Apixaban 5mg tablets 56 tablet £53.20 £61.50 -£8.30 Mometasone 0.1% cream 100 gram £6.03 £13.70 -£7.67 Inositol nicotinate 750mg tablets 112 tablet £43.37 £51.03 -£7.66 Fluoxetine 60mg capsules 30 capsule £6.74 £14.37 -£7.63 Tolbutamide 500mg tablets 28 tablet £6.71 £14.32 -£7.61 Fosinopril 20mg tablets 28 tablet £7.07 £14.64 -£7.57 Phenobarbital 15mg tablets 28 tablet £17.44 £24.85 -£7.41 Amlodipine 10mg/5ml oral solution sugar free 150 ml £115.70 £123.07 -£7.37 Clindamycin 150mg capsules 24 capsule £3.81 £10.89 -£7.08 Phenytoin sodium 100mg tablets 28 tablet £23.00 £30.00 -£7.00 Dexamethasone 2mg tablets 50 tablet £42.85 £49.09 -£6.24 Trospium chloride 20mg tablets 60 tablet £13.01 £19.01 -£6.00 Modafinil 200mg tablets 30 tablet £16.19 £21.99 -£5.80 Frovatriptan 2.5mg tablets 6 tablet £10.95 £16.67 -£5.72 Exemestane 25mg tablets 30 tablet £5.71 £11.37 -£5.66 Propylthiouracil 50mg tablets 56 tablet £59.47 £65.11 -£5.64 Page 3 of 6 Amiloride 5mg tablets 28 tablet £1.21 £6.72 -£5.51 Colestyramine 4g oral powder sachets sugar free 50 sachet £26.52 £31.85 -£5.33 Mefenamic acid 250mg capsules 100 capsule £9.54 £14.71 -£5.17 Mercaptopurine 50mg tablets 25 tablet £49.15 £54.27 -£5.12 Orlistat 120mg capsules 84 capsule £17.55 £22.40 -£4.85 Amlodipine 5mg/5ml oral solution sugar free 150 ml £75.74 £80.55 -£4.81 Inositol nicotinate 500mg tablets 100 tablet £26.15 £30.76 -£4.61 Levofloxacin 250mg tablets 10 tablet £7.15 £11.65 -£4.50 Fosinopril 10mg tablets 28 tablet £7.87 £12.24 -£4.37 Mometasone 0.1% ointment 100 gram £6.20 £10.43 -£4.23 Diclofenac sodium 75mg modified-release tablets 56 tablet £11.31 £15.50 -£4.19 Fenofibrate micronised 200mg capsules 28 capsule £4.54 £8.70 -£4.16 Clonidine 25microgram tablets 112 tablet £5.08 £9.15 -£4.07 Diamorphine 500mg powder for solution for injection vials 5 vial £205.00 £209.00 -£4.00 Temazepam 10mg tablets 28 tablet £1.89 £5.86 -£3.97 Temazepam 20mg tablets 28 tablet £1.91 £5.83 -£3.92 Levothyroxine sodium 50micrograms/5ml oral
Recommended publications
  • An Approach to the Patient with a Dry Mouth

    An Approach to the Patient with a Dry Mouth

    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
  • Stable Pressurised Aerosol Solution Composition of Glycopyrronium Bromide and Formoterol Combination

    Stable Pressurised Aerosol Solution Composition of Glycopyrronium Bromide and Formoterol Combination

    (19) TZZ¥¥_T (11) EP 3 384 898 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.10.2018 Bulletin 2018/41 A61K 9/00 (2006.01) A61M 15/00 (2006.01) A61K 31/167 (2006.01) A61K 31/40 (2006.01) (2006.01) (2006.01) (21) Application number: 18171127.6 B65D 83/54 A61K 31/573 A61K 31/54 (2006.01) A61K 45/06 (2006.01) (2006.01) (2006.01) (22) Date of filing: 23.12.2014 A61K 9/12 A61K 31/58 A61M 39/22 (2006.01) (84) Designated Contracting States: • COPELLI, Diego AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 43100 PARMA (IT) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • DAGLI ALBERI, Massimiliano PL PT RO RS SE SI SK SM TR 43100 PARMA (IT) Designated Extension States: • USBERTI, Francesca BA ME 43100 PARMA (IT) • ZAMBELLI, Enrico (30) Priority: 30.12.2013 EP 13199784 43100 PARMA (IT) (62) Document number(s) of the earlier application(s) in (74) Representative: Bianchetti Bracco Minoja S.r.l. accordance with Art. 76 EPC: Via Plinio, 63 14825154.9 / 3 089 735 20129 Milano (IT) (71) Applicant: Chiesi Farmaceutici S.p.A. Remarks: 43100 Parma (IT) This application was filed on 08-05-2018 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • BONELLI, Sauro 43100 PARMA (IT) (54) STABLE PRESSURISED AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION (57) The invention concerns an aerosol solution lower than the limit of quantification, when stored in ac- composition intended for use with a pressurised metered celerated conditions at 25°C and 60% relative humidity dose inhaler, comprising glycopyrronium bromide and (RH) for 6 months in a can internally coated by a resin formoterol, or a salt thereof or a solvate of said salt, op- comprising a fluorinated ethylene propylene (FEP) poly- tionally in combination with one or more additional active mer.
  • Pilocarpine (Systemic) | Memorial Sloan Kettering Cancer Center

    Pilocarpine (Systemic) | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Pilocarpine (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Salagen Brand Names: Canada JAMP Pilocarpine; M-Pilocarpine; Salagen What is this drug used for? It is used to treat dry mouth. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to pilocarpine or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Asthma, glaucoma, liver disease, or swelling in parts of the eye. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure Pilocarpine (Systemic) 1/6 that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • Hypersalivation in Children and Adults

    Hypersalivation in Children and Adults

    Pharmacological Management of Hypersalivation in Children and Adults Scope: Adult patients with Parkinson’s disease, children with neurodisability, cerebral palsy, long-term ventilation with drooling, and drug-induced hypersalivation. ASSESSMENT OF SEVERITY/RESPONSE TO TREATMENT: Severity of drooling can be assessed subjectively via discussion with patients and their carers/parents and by observation. Amount of drooling can be quantified by measuring the number of bibs required per day and this can also be graded using the Thomas-Stonell and Greenberg scale: • 1 = Dry (no drooling) • 2 = Mild (moist lips) • 3 = Moderate (wet lips and chin) • 4 = Severe (damp clothing) CONSIDERATIONS FOR PRESCRIBING/TITRATION No evidence to support the use of one particular treatment over another. Drug choice is to be determined by individual patient factors. When prescribing/titrating antimuscarinic drugs to treat hypersalivation always take account of: • Coexisting conditions (for example, history of urinary retention, constipation, glaucoma, dental issues, reflux etc.) • Use of other existing medication affecting the total antimuscarinic burden • Risk of adverse effects Titrate dose upward until the desired level of dryness, side effects or maximum dose reached. Take into account the preferences of the patients and their carers/ parents, and the age range and indication covered by the marketing authorisations (see individual summaries of product characteristics, BNF or BNFc for full prescribing information). FIRST LINE DRUG TREATMENT OPTIONS FOR ADULTS
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome

    The Role of Antispasmodics in Managing Irritable Bowel Syndrome

    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
  • 1: Gastro-Intestinal System

    1: Gastro-Intestinal System

    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
  • West Sussex Health and Social Care NHS Trust

    West Sussex Health and Social Care NHS Trust

    SUSSEX PARTNERSHIP NHS FOUNDATION TRUST MEDICINES FORMULARY GUIDELINE VERSION 26 RATIFYING GROUP (individual formulary Drugs and Therapeutics Group (DTG) decisions and linked guidelines) DATE PUBLISHED July 2021 NEXT REVIEW DATE July 2023 FORMULARY SPONSOR Chief Medical Officer FORMULARY EDITOR Chief Pharmacist LINKED POLICIES AND GUIDELINES Linked policies and antipsychotic Physical health linked guidelines guidelines • Antipsychotics, guidelines for cardiac • Antipsychotics, prescribing guidelines rhythm screening (ECGs) • Asenapine, prescribing guidelines • Antipsychotics, guidelines for the • Clozapine inpatient and community management of weight gain and team policies metabolic disturbances • Clozapine, protocol for the use of • Metformin, information for GPs on its intramuscular injection use with antipsychotics • Clopixol Acuphase, prescribing • Hyperprolactinaemia, prescribing guideline guidelines on the treatment of • Lurasidone, prescribing guidelines antipsychotic induced symptoms • Perinatal mental health, prescribing • Anticoagulants, prescribing guidelines guidelines • Insulin, prescribing guidelines • Rapid tranquilisation policy • Medicines code Long acting antipsychotic guidelines Anxiolytics and hypnotic guidelines • Long acting antipsychotic injections, • Alcohol and benzodiazepine guidelines for use dependence (adults), prescribing • Aripiprazole long acting injection, guidelines for inpatients • Benzodiazepine as anxiolytics (adults), prescribing guidelines prescribing guidelines • Olanzapine long-acting injection,
  • Drug Class Review Ophthalmic Cholinergic Agonists

    Drug Class Review Ophthalmic Cholinergic Agonists

    Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods .......................................................................................................................................
  • Association Between N-Desmethylclozapine and Clozapine-Induced Sialorrhea

    Association Between N-Desmethylclozapine and Clozapine-Induced Sialorrhea

    JPET Fast Forward. Published on August 29, 2020 as DOI: 10.1124/jpet.120.000164 This article has not been copyedited and formatted. The final version may differ from this version. 1 Title page Association between N-desmethylclozapine and clozapine-induced sialorrhea: Involvement of increased nocturnal salivary secretion via muscarinic receptors by N- desmethylclozapine Downloaded from Authors and Affiliations: Shuhei Ishikawa, PhD1, 2, a, Masaki Kobayashi, PhD1, 3, *, Naoki Hashimoto, PhD, jpet.aspetjournals.org MD4, Hideaki Mikami, BPharm1, Akihiko Tanimura, PhD5, Katsuya Narumi, PhD1, Ayako Furugen, PhD1, Ichiro Kusumi, PhD, MD4, and Ken Iseki, PhD1 at ASPET Journals on September 23, 2021 1 Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University 2 Department of Pharmacy, Hokkaido University Hospital 3 Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University 4 Department of Psychiatry, Hokkaido University Graduate School of Medicine 5 Department of Pharmacology, School of Dentistry, Health Sciences University of Hokkaido a Present address: Department of Psychiatry, Hokkaido University Hospital JPET Fast Forward. Published on August 29, 2020 as DOI: 10.1124/jpet.120.000164 This article has not been copyedited and formatted. The final version may differ from this version. 2 Running title page Association between N-desmethylclozapine and CIS Corresponding author: Masaki Kobayashi Downloaded from Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, jpet.aspetjournals.org Kita-ku, Sapporo 060-0812, Japan. Phone/Fax: +81-11-706-3772/3235. E-mail: [email protected] at ASPET Journals on September 23, 2021 Number of text pages: 25 Number of tables: 1 Number of figures: 6 Number of words in the Abstract: 249 Number of words in the Introduction: 686 Number of words in the Discussion: 1492 JPET Fast Forward.
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’

    Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’

    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.